CDK
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB16475 | Trilaciclib | 1374743-00-6 | Trilaciclib is an inhibitor of CDK4 and CDK6 with IC50s of 1 nM and 4 nM, respectively. |
| FB16070 | TP353 | 1253799-29-9 | TP353 is a CDK7 inhibitor. |
| FB11095 | THZ531 | 1702809-17-3 | THZ531 is a covalent CDK12 and CDK13 inhibitor with IC50s of 158 nM and 69 nM. |
| FB11910 | THAL-SNS-032 | 2139287-33-3 | THAL-SNS-032 is a selective PROTAC, consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN), targeting on CDK9. |
| FB15239 | SB1317 | 1204918-72-8 | TG02 (Double bond E) is the Double key form of TG02. TG02 is a small molecule potent CDK2/JAK2/FLT3 inhibitor with IC50s of 13/73/56 nM respectively. |
| FB10087 | TG003 | 300801-52-9 | TG003 is a potent, reversible ATP-competitive inhibitor of Cdc-2 like kinase (Clk) with IC50s of 20 nM and 15 nM for Clk1/Sty and Clk4. |
| FB17204 | TAK-931 | 1330782-76-7 | TAK-931 is an oral CDC7-selective inhibitor as a candidate clinical anticancer drug. It induced S phase delay and replication stress. |
| FB17259 | SY-1365 | 1816989-16-8 | SY-1365 is a first-in-class selective CDK7 inhibitor with Ki of 17.4 nM. |
| FB00220 | SU9516 (mixture) | 666837-93-0 | SU9516 (mixture) is a 3-substituted indolinone compound and a competitive inhibitor of CDC2 CDK2 and CDK4 that displaying anti-proliferative and proapoptotic properties in tumor cells. It is the mixture form of SU9516. |
| FB16554 | SR-4853 | 2387704-62-1 | SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 with IC50 of 99 nM, Kd of 98 nM for CDK12 and Kd of 4.9 nM for CDK13. It acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death. |
| FB13149 | SEL120-34A HCl | 1609452-30-3 | SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity. |
| FB10878 | Roniciclib | 1223498-69-8 | Roniciclib is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity, selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. |
| FB11924 | CDK9-PROTAC | 2118356-96-8 | PROTAC CDK9 Degrader-1 is a CRBN-recruiting PROTAC selectively targeting on CDK9, consist of a CDK9 ligand (aminopyrazole analog) linked to a CRBN E3 ligand thalidomide. |
| FB16751 | PNU 112455A | 21886-12-4 | PNU112455A HCl is an ATP site competetive inhibitor of CDK2 and CDK5. The Km for binding to the ATP site of CDK2 and CDK5 is 3.6 and 3.3 mM, respectively. |
| FB17549 | NVP-2 | 1263373-43-8 | NVP-2 is a potent and selective ATP-competitive CDK9 inhibitor with IC50 value of 0.5nM. |
| FB16550 | NU6140 | 444723-13-1 | NU6140 is a selective CDK2 inhibitor with IC50 value of 0.94μM, as well as potently inhibits Aurora kinase A/B with IC50 values of 0.035 and 0.067μM, respectively. |
| FB16469 | NSC-95397 | 93718-83-3 | NSC 95397 is irreversible Cdc25 dual specificity phosphatase inhibitor with Ki values of 32, 96, and 40 nM for Cdc25A, Cdc25B, and Cdc25C, respectively. |
| FB18846 | LY3143921 hrdrate | 1627696-53-0 | LY3143921 is an orally administered ATP-competitive inhibitor of CDC7 with potential antineoplastic activity. |
| FB11169 | LDC4297 | 1453834-21-3 | LDC4297 is a potent CDK7 selective inhibitor with IC50 of 0.13 ± 0.06 nM. |
| FB17202 | JSH-150 | 2247481-21-4 | JSH-150 is a highly selective CDK9 kinase inhibitor with IC50 value of 1nM. It dose-dependently inhibited the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrested the cell cycle and induced the apoptosis in the leukemia cells. |
| FB11907 | JH-XI-10-02 | 2209085-22-1 | JH-XI-10-02 is a PROTAC selectively targeting on CDK8 with IC50 value of 159nM, and is consist of a warhead target on CDK8 (a Cortistatin A derivate) linked to CRBN ligand Pomalidomide. |
| FB11731 | FN-1501 | 1429515-59-2 | FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively; has anticancer activity. |
| FB16035 | EHT 5372 | 1425945-60-3 | EHT 5372 is a strong inhibitor of DYRK’s family kinases, with IC50s of 0.22, 0.28 nM for DYRK1A and DYRK1B, respectively. |
| FB18835 | Dalpiciclib | 1637781-04-4 | Dalpiciclib is a novel CDK 4/6 inhibitor which demonstrated promising anti-tumor potency in preclinical models. |
| FB11577 | CT7001 HCl | 1805789-54-1 | CT7001 HCl is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively. |
| FB19684 | CP5V | 2509359-75-3 | CP5V is a PROTAC targeting on Cdc20 with DC50 value of 1.6μM, comprising a Cdc20 ligand and VHL binding moiety bridged by a PEG5 linker. It leads to significant inhibition of breast cancer cell proliferation and resensitization of Taxol-resistant cell lines and suppressed breast tumor progression in vivo. |
| FB19600 | CP-10 | 2366268-80-4 | CP-10 is a PROTAC targeting on CDK4/6 with DC50 values of 150-180 nM and 2.1 nM, respectively. It was generated by linking CDK6 inhibitor palbociclib and E3 ligase CRBN recruiter pomalidomide. |
| FB11987 | CMPD 7 | 2220184-50-7 | CMPD 7 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay. |
| FB11976 | CDK8/19-IN-1 | 1818427-07-4 | CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively. |
| FB11978 | CDK8-IN-4 | 1613638-82-6 | CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM. |
| FB11977 | CDK8-IN-3 | 1884500-15-5 | CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7. |
| FB17209 | CDK2 inhibitor 73 | 2079895-42-2 | CDK2 inhibitor 73 is a selective CDK2 inhibitor with IC50 value of 44nM. |
| FB15275 | cc671 | 1618658-88-0 | CC-671 is a selective inhibitor of TTK (Mps1) and CLK2 with IC50s of 5 nM and 3 nM, respectively. |
| FB19662 | BSJ-04-132 | 2349356-39-2 | BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC), with IC50s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity. |
| FB15443 | BSJ-03-123 | 2361493-16-3 | BSJ-03-123 is a PROTAC selectively targeting on CDK6, consist of a warhead palbociclib (a CDK inhibitor) linked to a CRBN ligand pomalidomide. |
| FB16449 | BS-194 | 1092443-55-4 | BS-194 is a selective and potent CDK inhibitor with IC50 values of 3, 30, 30, 250, and 90nM for CDK2, CDK1, CDK5, CDK7, and CDK9, respectively. |
| FB00653 | Briciclib | 865783-99-9 | Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells. |
| FB11329 | BRD6989 | 642008-81-9 | BRD6989 selectively upregulates IL-10 through inhibiting CDK8 activity. |
| FB16303 | Bohemine | 189232-42-6 | Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 µM. Bohemine is structurally similar to Olomoucine and Roscovitine. |
| FB16509 | BI-1347 | 2163056-91-3 | BI-1347 is a potent CDK8 inhibitor with an IC50 of 1.1 nM. |
| FB10513 | AZD5438 | 602306-29-6 | AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM. |
| FB10513 | AZD5438 | 602306-29-6 | AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM. |
| FB15987 | AZD4573 | 2057509-72-3 | AZD4573 is a potent and selective CDK9 inhibitor with with nanomolar. |
| FB11590 | Atuveciclib Racemate | 1414943-88-6 | Atuveciclib Racemate is the racemate form of Atuveciclib. |
| FB16876 | Atuveciclib | 1414943-94-4 | Atuveciclib is an orally available and selective PTEFb/CDK9 inhibitor for the treatment of cancer. |
| FB11730 | AMG925 HCl | 1401034-19-2 | AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively. |
| FB12599 | Alsterpaullone | 237430-03-4 | Alsterpaullone is a potent CDK1 and 2 inhibitor with IC50s of 0.035 and 0.08 μM, respectively. It also inhibits GSK-3β and Lck with IC50s of 0.11 and 0.47 μM, respectively. |
| FB17556 | (±)-BAY-1251152 | 1610358-53-6 | (±)-BAY-1251152 is a racemic mixture form of BAY-1251152. BAY 1143572 is the first selective, orally available PTEFb/CDK9 inhibitor that entered clinical development with IC50 value of 3nM. |
| FB12209 | (R)-CR8 | 294646-77-8 | (R)-CR8 is a cyclin dependent kinase (cdk) inhibitor with IC50 of 0.036 - 0.07 and 0.09 - 0.8 μM for cdk2 and cdk1,respectively. |
| FB17302 | (-)-((2-((5-Fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)amino)pyridin-4-yl)methyl)(imino)(methyl)-l6-sulfanone | 1610358-59-2 | (-)-BAY-1251152 is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. |